Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod IV vs SC in Healthy Subjects
NCT04564066Phase 1Completed
- Sponsor
- argenx
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (2 arms), sponsored by argenx. Primary endpoint: Percentage reduction in total IgG levels at Day 29. Started Aug 2020; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04564066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564066.